about
The role of fibrin matrices and tissue factor in early-term trophoblast proliferation and spreadingHeparanase enhances the generation of activated factor X in the presence of tissue factor and activated factor VIITravel-related thrombosis: is this a problem?A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriagesWomen, thrombosis, and cancer: A gender-specific analysis.Vitamin K-dependent coagulation factors deficiency.IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life.Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated factor VII.A fatal case of enoxaparin induced skin necrosis and thrombophilia.Hemorrhagic and thrombotic complications in bone marrow transplant recipients.Bleeding and thrombosis in acute leukemia: what does the future of therapy look like?Enoxaparin use in pregnancy: state of the art.Pulmonary hemorrhage: A novel mode of therapy.p45 NF-E2 regulates syncytiotrophoblast differentiation by post-translational GCM1 modifications in human intrauterine growth restriction.Haemostatic changes in pregnancy.Thrombohemorrhagic complications of myeloproliferative disorders.Coagulation and placenta-mediated complications.Coagulation and mental disordersVTE Registry: What Can Be Learned from RIETE?Implementing thrombosis guidelines in cancer patients: a review.Emerging options in the treatment of deep vein thrombosis and pulmonary embolism.Orthostatic hypercoagulability: a novel physiological mechanism to activate the coagulation system.Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.Thrombophilia and pregnancy loss.Cryogenic transmission electron microscopy nanostructural study of shed microparticles.Thrombophilia and fetal loss.Procoagulant and anticoagulant mechanisms in human placenta.Haemostatic mechanisms in human placenta.Inherited thrombophilia and poor pregnancy outcome.Clinical management of thrombophilia-related placental vascular complications.Risk factors for recurrent venous thromboembolism in the European collaborative paediatric database on cerebral venous thrombosis: a multicentre cohort study.Thrombophilia related issues in women and children.Inhalation of a Short-Acting β2-Adrenoreceptor Agonist Induces a Hypercoagulable State in Healthy Subjects.Maternal extracellular vesicles and platelets promote preeclampsia via inflammasome activation in trophoblasts.Drug-related thrombosis in hematologic malignancies.Prevalence of upper extremity deep venous thrombosis diagnosed by color Doppler duplex sonography in cancer patients with central venous catheters.Heparanase-A Link between Coagulation, Angiogenesis, and Cancer.Heparanase, heparin and the coagulation system in cancer progression.Heparanase, tissue factor, and cancer.Corpus luteum hemorrhage in women with bleeding disorders.
P50
Q24336393-2DDC090A-6891-46FE-96FB-A1CAC6C7C41DQ24338856-662C2D59-2B5F-4D0A-A5AF-AAE1148962DEQ28217525-15855ACD-EF8D-4CC1-9F16-2B8E9641B5DAQ28219011-CCC2AF95-023D-4012-9270-7162AF67C523Q30235425-3DE104AA-71AB-4F94-9A52-8412BA1355A2Q30378913-67BFCDAD-6BC7-4F4A-B9B6-99053AAF26E2Q33360133-DBE426DA-7E43-464E-8057-BD2AE655608BQ33369021-BFD193DD-972F-4112-84A5-B0ECD2AD653CQ33372023-75FF7E63-7585-4644-B5DA-3F5CEFF6CA42Q33377451-605385F4-7022-4CB6-AA6B-A3F54320DA94Q33377454-CD776D56-39EE-40EC-A4DA-64B71E04DD2DQ33386499-B1338B2C-92CC-48D7-911E-110DF80F3D23Q33413553-CCE48676-4809-4CBC-8D65-9CC368782EFFQ33815861-C994DABF-2BBA-4369-BAD3-C347E11D17E6Q33982652-DAD90934-D9CC-405E-9B39-96EE60E6ABFAQ34136065-C60A79E3-CE49-40F6-8D42-DDFD054DA916Q34463447-57487556-83D1-4FDB-A043-D1CA9D9251B0Q34463453-00C2417C-ADBB-4912-B899-681C8FD314F1Q34463461-45B0A300-2A64-4CE6-A7C2-B3B4006F0B7EQ34463482-EBED7B99-64A2-4B86-947B-93C7EE9E2EFDQ34629438-7827DD29-C81F-4C4D-ADD6-86CCFB3EBAEBQ34769965-971DE17D-26DE-4E6B-AA6E-AAD7A7FAAECAQ34789474-F2F3ED54-6ADA-438C-9CDA-87C9A3A01569Q35078350-3CC59667-1D1F-477A-A259-8FC8C94CF3C9Q35080565-336FEB9B-FBFD-47F8-BBF9-709E5F4D1A42Q35112733-EB4146E1-6AC6-4435-A303-189BE35F24E0Q35112739-365DE2EB-020B-46B7-922F-DA41D2F02956Q35134502-0630F1E7-27F3-4F67-9395-D7756CA3E458Q35145560-0D81D43B-4450-486A-A048-2649BDDAE204Q35667045-50F85AD4-795C-45D8-82F8-16553E5D93C9Q35868806-CAB6DC2F-6C45-4548-BECB-0B2BEDA7279EQ36038553-6243D919-88AB-4204-8E85-7B2683C1B3BEQ36068244-88F66321-913B-4F83-BC78-F21CF5380ECAQ36121912-6808F66B-FE3D-4084-87D5-19ADEBFBD3DDQ36200616-0644E970-8ECE-478E-BBC3-7705A8EC3270Q36602368-7B525A2B-997C-45B7-8353-9172D3520FA1Q36999958-8A6920DA-4CA1-4D28-8C15-18BABC225AD9Q37006624-76D20725-A622-4A46-9250-3C71E55A0988Q37223513-26F86DF9-2F88-413F-A49B-19D3319C53E0Q37356484-6E01525C-7B55-48CF-A2C0-B21ED5FC4085
P50
name
Benjamin Brenner
@en
Benjamin Brenner
@nl
type
label
Benjamin Brenner
@en
Benjamin Brenner
@nl
prefLabel
Benjamin Brenner
@en
Benjamin Brenner
@nl